Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

  title={Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men},
  author={Anja Blumeyer and Antonella Tosti and Andrew G Messenger and Pascal Reygagne and V{\'e}ronique del Marmol and Phyllis I. Spuls and Myrto Georgia Trakatelli and Andreas M. Finner and Franklin Kiesewetter and Ralph M Tr{\"u}eb and Berthold Br Rzany and Ulrike Blume-Peytavi},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. 

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

The purpose of the guideline is to provide dermatologists with an evidence‐based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

Androgenetic Alopecia: An Update of Treatment Options

The current treatment alternatives for androgenetic alopecia including their efficacy, safety profile, and quality of evidence are discussed.

Guidelines for management of androgenetic alopecia based on BASP classification–the Asian consensus committee guideline

  • W. S. LeeH. Lee M. Zheng
  • Medicine
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2013
There is currently no published AGA guideline for Asian patients, and in comparison with Caucasian patients, Asian patients with AGA have different types of hair loss and family histories which may alter the treatment response.

Efficacy of platelet‐rich plasma in androgenetic alopecia patients

This study aims to use platelet‐rich plasma (PRP) as an alternative treatment option for the AGA patients and shows promising results.

Low‐level laser therapy as a treatment for androgenetic alopecia

This paper aims to review the existing research studies to determine whether LLLT is an effective therapy for AGA based on objective measurements and patient satisfaction.

Androgenetic Alopecia in Adolescents

Androgenetic alopecia (AGA) is a nonscarring progressive miniaturization of the hair follicle with a usually characteristic pattern distribution in genetically predisposed men and women. Although AGA

Expert consensus on the management of Androgenetic Alopecia in India

This review articulately summarizes the key opinions of the experts on all aspects of treatment for the effective management of AGA and provides the dermatologists with an evidence-based platform for choosing efficacious and safe therapy for patients with AGA.

Тіе Modern treatment of androgenetic alopecia

Growth factors and cytokines, topical 5-alpha-reductase inhibitors, androgen receptor antagonists, prostaglandin analogs and antagonists, Wnt signaling activators and platelet-rich plasma injections are discussed.

Addressing androgenetic alopecia–a complex disorder–with a multilateral treatment strategy

Hair follicle miniaturization and variations in normal hair cycle cause gradual loss of hair in genetically predisposed individuals and leads to global reduction of hair density due to conversion of terminal hair into vellus hair.



S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents

This S1 guideline for diagnostic evaluation of AGA in men, women and adolescents reviews the definition of AGA and presents expert opinion‐based recommendations for sex‐dependent steps in the diagnostic procedure.


This study focuses on the treatment of hair loss in women withAndrogenetic alopecia, which begins as a diffuse and progressive thinning of the frontoparietal area of the scalp in women.

[Alopecia androgenetica and its local treatment with estrogen- and corticosteroid externa].

Treatment of androgenetic alopecia in 50 male and female patients with topical estorgens and corticosteroids with suggested that estrogens may limit the effect of endogenous testosterone in exhausting the hair follicle.

Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial

The effect of melatonin on hair growth in humans has not been investigated so far, but the effects of testosterone and dihydrotestosterone on the hair cycle are known to have an important role.

Incidence of Female Androgenetic Alopecia (Female Pattern Alopecia)

  • O. Norwood
  • Medicine
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2001
Female androgenetic alopecia is quite common beginning in the late 20s and reaching its peak after 50 years of age.

Androgenetic alopecia in adolescents.

An overview of AGA is provided and new information on the prevalence and age at onset of hereditary hair thinning in adolescents is presented and data are presented on the efficacy and proper use of minoxidil topical solution in adolescent boys and girls.

Male Androgenetic Alopecia

• Male balding is a common androgen-dependent trait in which there is a progressive decline in the activity and size of scalp hair follicles.

Lokaltherapie der Alopecia androgenetica mit 17α-Östradiol

In a controlled, randomized double-blind study, 51 patients with androgenetic alopecia and increased hair loss (telogen rate > 20%) were treated by local application of hair lotions with and without 1

Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women

Background: Two drugs which are approved for the treatment of androgenetic alopecia in women in Germany were compared with regard to their influence on hair growth.